Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1211-1220 of 1,298) with videos related to

Pageof 130
Sort By:
Cell Genomics|February 13, 2023
Multi-omics characterization of silent and productive HPV integration in cervical cancerJunpeng Fan, Yu Fu, Wenju Peng, et al.
Genome Biology|May 13, 2015
Erratum to: Modeling precision treatment of breast cancerAnneleen Daemen, Obi L Griffith, Laura M Heiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Genome Biology|November 2, 2013
Modeling precision treatment of breast cancerAnneleen Daemen, Obi L Griffith, Laura M Heiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
EMBO Molecular Medicine|April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanomaIleabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Cancer Research|July 16, 2009
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinomaMatthew Maurer, Tao Su, Lao H Saal, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Pageof 130

Showing results (1211-1220 of 1,298) with videos related to

Sort By:
Pageof 130
Cell Genomics|February 13, 2023
Multi-omics characterization of silent and productive HPV integration in cervical cancerJunpeng Fan, Yu Fu, Wenju Peng, et al.
Genome Biology|May 13, 2015
Erratum to: Modeling precision treatment of breast cancerAnneleen Daemen, Obi L Griffith, Laura M Heiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Genome Biology|November 2, 2013
Modeling precision treatment of breast cancerAnneleen Daemen, Obi L Griffith, Laura M Heiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
Cancer Research|June 6, 2013
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft modelsXiaomei Zhang, Sofie Claerhout, Aleix Prat, et al.
EMBO Molecular Medicine|April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanomaIleabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Cancer Research|July 16, 2009
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinomaMatthew Maurer, Tao Su, Lao H Saal, et al.
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Pageof 130